KRAS and pancreatic intraductal papillary-mucinous neoplasm: Additionally, overall survival was decreased in the presence of detectable ctDNA and KRAS mutation with 2.25 and 1.52 increased risks.26 Nonetheless, the role of such markers in prognosticating IPMN and other PCLs remains to be elucidated.